Thoracic aortic aneurysm (TAA) is a silent disease, often discovered at a time point that dramatic complications, as rupture and dissection, occur. For the detection of asymptomatic TAA and prevention of such complications, it is essential to have an adequate screening tool. Until now, routine laboratory blood tests have played only a minor role in the screening, diagnosis, tracking and prediction of the natural history of TAAs. However, the knowledge about biomarkers is rapidly expanding in the cardiovascular field, and there are several potential biomarkers that might be implemented into TAA clinical practice in the near future. The most important and promising markers for TAA will be discussed in this overview.
Biomarkers in TAA—The Holy Grail / G.H.W. van Bogerijen, J.L. Tolenaar, V. Grassi, C. Lomazzi, S. Segreti, V. Rampoldi, J.A. Elefteriades, S. Trimarchi. - In: PROGRESS IN CARDIOVASCULAR DISEASES. - ISSN 0033-0620. - 56:1(2013 Jul), pp. 109-115. [10.1016/j.pcad.2013.05.004]
Biomarkers in TAA—The Holy Grail
V. Rampoldi;S. Trimarchi
2013
Abstract
Thoracic aortic aneurysm (TAA) is a silent disease, often discovered at a time point that dramatic complications, as rupture and dissection, occur. For the detection of asymptomatic TAA and prevention of such complications, it is essential to have an adequate screening tool. Until now, routine laboratory blood tests have played only a minor role in the screening, diagnosis, tracking and prediction of the natural history of TAAs. However, the knowledge about biomarkers is rapidly expanding in the cardiovascular field, and there are several potential biomarkers that might be implemented into TAA clinical practice in the near future. The most important and promising markers for TAA will be discussed in this overview.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
